BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Eslam M, Aparcero R, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, Romero-Gomez M. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther 2011;34:297-305. [PMID: 21623851 DOI: 10.1111/j.1365-2036.2011.04716.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Li M, Huang Z, Shan Q, Chen S, Zhang N, Hu H, Wang W. Performance and comparison of artificial intelligence and human experts in the detection and classification of colonic polyps. BMC Gastroenterol 2022;22:517. [DOI: 10.1186/s12876-022-02605-2] [Reference Citation Analysis]
2 Urganci N, Kalyoncu D, Geylani-gulec S. Resistencia a la insulina en niños con hepatitis C crónica y su asociación con la respuesta al IFN-alfa y ribavirina. Revista de Gastroenterología de México 2021;86:140-144. [DOI: 10.1016/j.rgmx.2020.07.002] [Reference Citation Analysis]
3 Simon KG, Serfert Y, Buggisch P, Mauss S, Boeker KHW, Klinker H, Müller T, Merle U, Hüppe D, Manns MP, Wedemeyer H. [Evolution of hepatitis C virus genotype 1a vs. 1b distribution in Germany between 2004 and 2018 - An analysis of 17093 patients from different real world registries]. Z Gastroenterol 2021;59:241-9. [PMID: 33684956 DOI: 10.1055/a-1332-2214] [Reference Citation Analysis]
4 Degasperi E, Colombo M. Natural History of Hepatitis C Infection. Hepatitis C: Epidemiology, Prevention and Elimination 2021. [DOI: 10.1007/978-3-030-64649-3_7] [Reference Citation Analysis]
5 Lee KW, Shin D. Positive association between dietary acid load and future insulin resistance risk: findings from the Korean Genome and Epidemiology Study. Nutr J 2020;19:137. [PMID: 33292308 DOI: 10.1186/s12937-020-00653-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
6 Abd El-wahab EW, Ayoub HA, Shorbila AA, Mikheal A, Fadl M, Kotkat AM. Noninvasive biomarkers predict improvement in liver fibrosis after successful generic DAAs based therapy of chronic hepatitis C in Egypt. Clinical Epidemiology and Global Health 2020;8:1177-88. [DOI: 10.1016/j.cegh.2020.04.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
7 Zuo Z, Jiang Y, Zeng S, Li Y, Fan J, Guo Y, Tao H. The value of microRNAs as the novel biomarkers for colorectal cancer diagnosis: A meta-analysis. Pathol Res Pract 2020;216:153130. [PMID: 32853954 DOI: 10.1016/j.prp.2020.153130] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Bogomolov PO, Bueverov AO, Fedosina EA, Bakirova VE, Koblov SV. Clinical parallels and experience of antivira l therapy in chronic hepatitis with polycystic ovary syndrome. jour 2020;174:71-79. [DOI: 10.31146/1682-8658-ecg-174-2-71-79] [Reference Citation Analysis]
9 Johnson LP, Sterling RK. The Prevalence and Impact of Hepatic Steatosis on Response to Direct-Acting Antiviral Therapy in HIV-HCV Coinfection. Biology (Basel) 2020;9:E87. [PMID: 32344543 DOI: 10.3390/biology9040087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Hu JH, Chang ML, Liu NJ, Yeh CT, Huang TJ. Effect of HCV treatment response on insulin resistance: A systematic review and meta-analysis. Exp Ther Med 2019;18:3568-78. [PMID: 31602234 DOI: 10.3892/etm.2019.7995] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
11 Li Y, Wang X, Yu G, Sun H, Lv J, Chi X, Wu R, Gao X, Niu J. The association of hepatitis c virus infection status with serum glucose levels. BMC Gastroenterol. 2019;19:86. [PMID: 31195990 DOI: 10.1186/s12876-019-1003-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
12 Altın Z, Diniz G, Çolak A, Koyuncu B, Özer S, Aslan F, Ünsal B. Influence of pegylated interferon and ribavirin on insulin resistance and metabolic factors in chronic hepatitis C. Turkish Journal of Biochemistry 2019;44:170-176. [DOI: 10.1515/tjb-2018-0163] [Reference Citation Analysis]
13 Elhelbawy M, Abdel-Razek W, Alsebaey A, Hashim M, Elshenawy H, Waked I. Insulin resistance does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the treatment. Eur J Gastroenterol Hepatol 2019;31:16-23. [PMID: 30024489 DOI: 10.1097/MEG.0000000000001215] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
14 Laurito MP, Silva GF, Cheinquer H, Sharma R, Verna E, Parise ER. DOES INSULIN RESISTANCE IMPAIR THE VIROLOGICAL RESPONSE TO PEGINTERFERON/RIBAVIRIN IN CHRONIC HEPATITIS C GENOTYPE 3 PATIENTS? Arq Gastroenterol 2018;55:179-83. [PMID: 30043870 DOI: 10.1590/S0004-2803.201800000-32] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
15 Zubkin ML, Chervinko VI, Ovchinnikov YV, Kryukov EV, Kotenko ON. [Chronic HCV infection: An internist's opinion (Part 2)]. Ter Arkh 2016;88:138-48. [PMID: 28635834 DOI: 10.17116/terarkh20168811138-148] [Reference Citation Analysis]
16 Shahnazarian V, Ramai D, Reddy M, Mohanty S. Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges. Ann Gastroenterol 2018;31:541-51. [PMID: 30174390 DOI: 10.20524/aog.2018.0281] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
17 Bilić-ćurčić I, Roguljić H, Ivandić M, Včev A, Smolić R, Smolić M. Hepatitis C–Associated Diabetes Mellitus. Update on Hepatitis C 2017. [DOI: 10.5772/intechopen.70721] [Reference Citation Analysis]
18 Yen YH, Chen JF, Wu CK, Lin MT, Chang KC, Tseng PL, Tsai MC, Lin JT, Hu TH. The correlation of controlled attenuation parameter results with ultrasound-identified steatosis in real-world clinical practice. J Formos Med Assoc 2017;116:852-61. [PMID: 28888355 DOI: 10.1016/j.jfma.2017.08.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
19 Cacoub P, Comarmond C, Desbois AC, Saadoun D. Rheumatologic Manifestations of Hepatitis C Virus Infection. Clin Liver Dis 2017;21:455-64. [PMID: 28689585 DOI: 10.1016/j.cld.2017.03.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
20 Gane EJ, DeJesus E, Janczewska E, George J, Diago M, Da Silva MH, Reesink H, Nikitin I, Hinrichsen H, Bourgeois S, Ferenci P, Shukla U, Kalmeijer R, Lenz O, Fevery B, Corbett C, Beumont M, Jessner W. Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study. BMC Infect Dis 2017;17:389. [PMID: 28577353 DOI: 10.1186/s12879-017-2444-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
21 Desbois AC, Cacoub P. Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review. World J Gastroenterol 2017; 23(9): 1697-1711 [PMID: 28321170 DOI: 10.3748/wjg.v23.i9.1697] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 69] [Article Influence: 10.7] [Reference Citation Analysis]
22 Cacoub P, Commarmond C, Sadoun D, Desbois AC. Hepatitis C Virus Infection and Rheumatic Diseases. Rheumatic Disease Clinics of North America 2017;43:123-32. [DOI: 10.1016/j.rdc.2016.09.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
23 Lin M, Pappas SC. Diabetes, Specific Hepatobiliary Diseases, and Treatment. Managing Gastrointestinal Complications of Diabetes 2017. [DOI: 10.1007/978-3-319-48662-8_7] [Reference Citation Analysis]
24 Stine JG, Wynter JA, Niccum B, Kelly V, Caldwell SH, Shah NL. Effect of Treatment with Direct Acting Antiviral on Glycemic Control in Patients with Diabetes Mellitus and Chronic Hepatitis C. Ann Hepatol 2017;16:215-20. [PMID: 31153414 DOI: 10.5604/16652681.1231581] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
25 Shah SR, Rao PN, Sarin SK, Chowdhury A, Bhatia S, Dharamsi R, Goswami BD, Kapoor D, Luaia R, Mehta R, Mukewar S, Prasad VG, Rai RR, Saigal S, Singh D, Trehanpati N, Chen S, Gaggar A, Knox SJ, Subramanian GM, Singh SP, Sood A, Varghese J, Venugopal RV. Chronic hepatitis C virus infection in India: Regional demographics and distribution of viral genotypes. Indian J Gastroenterol 2016;35:469-77. [PMID: 27844277 DOI: 10.1007/s12664-016-0709-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
26 Stevenson HL, Utay NS. Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era. Trop Dis Travel Med Vaccines 2016;2:21. [PMID: 28883965 DOI: 10.1186/s40794-016-0038-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
27 Doyle MA, Singer J, Lee T, Muir M, Cooper C. Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial. Trials. 2016;17:331. [PMID: 27439433 DOI: 10.1186/s13063] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Doyle MA, Singer J, Lee T, Muir M, Cooper C. Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial. Trials 2016;17:331. [PMID: 27439433 DOI: 10.1186/s13063-016-1454-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
29 Kralj D, Virović Jukić L, Stojsavljević S, Duvnjak M, Smolić M, Čurčić IB. Hepatitis C Virus, Insulin Resistance, and Steatosis. J Clin Transl Hepatol 2016;4:66-75. [PMID: 27047774 DOI: 10.14218/JCTH.2015.00051] [Cited by in Crossref: 58] [Cited by in F6Publishing: 62] [Article Influence: 8.3] [Reference Citation Analysis]
30 Oliveira LP, de Jesus RP, Boulhosa RS, Onofre T, Mendes CM, Vinhas L, Waitzberg DL, Lemaire DC, Cavalcante LN, Lyra AC, Lyra LG. Factors Associated with Insulin Resistance in Patients with Chronic HCV Genotype 1 Infection without Obesity or Type 2 Diabetes. J Am Coll Nutr 2016;35:436-42. [PMID: 26933768 DOI: 10.1080/07315724.2015.1072756] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
31 Knobler H, Malnick S. Hepatitis C and insulin action: An intimate relationship. World J Hepatol 2016; 8(2): 131-138 [PMID: 26807209 DOI: 10.4254/wjh.v8.i2.131] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
32 Negro F, Forton D, Craxì A, Sulkowski MS, Feld JJ, Manns MP. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology 2015;149:1345-60. [PMID: 26319013 DOI: 10.1053/j.gastro.2015.08.035] [Cited by in Crossref: 260] [Cited by in F6Publishing: 277] [Article Influence: 32.5] [Reference Citation Analysis]
33 Naing C, Sitt T, Aung AT, Aung K. Sustained Virologic Response to a Dual Peginterferon alfa-2a and Ribavirin in Treating Chronic hepatitis C Infection: A Retrospective Cohort Study. Medicine (Baltimore). 2015;94:e1234. [PMID: 26222859 DOI: 10.1097/md.0000000000001234] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
34 Chien CH, Lin CL, Hu CC, Chang JJ, Chien RN. Clearance of Hepatitis C Virus Improves Insulin Resistance During and After Peginterferon and Ribavirin Therapy. J Interferon Cytokine Res. 2015;35:981-989. [PMID: 26308911 DOI: 10.1089/jir.2014.0200] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
35 Freire TO, Boulhosa RS, Oliveira LP, de Jesus RP, Cavalcante LN, Lemaire DC, Toralles MB, Lyra LG, Lyra AC. n-3 polyunsaturated fatty acid supplementation reduces insulin resistance in hepatitis C virus infected patients: a randomised controlled trial. J Hum Nutr Diet 2016;29:345-53. [PMID: 26216648 DOI: 10.1111/jhn.12327] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
36 Romero-Gómez M, Turnes J, Ampuero J, Oyagüez I, Cuenca B, Gonzalez-Garcia J, Muñoz-Molina B, Aguilar R, Leal S, Planas R, Garcia-Samaniego J, Diago M, Crespo J, Calleja JL, Casado MA, Sola R. Prediction of week 4 virological response in hepatitis C for making decision on triple therapy: the Optim study. PLoS One 2015;10:e0122613. [PMID: 25826755 DOI: 10.1371/journal.pone.0122613] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
37 Grasso A, Malfatti F, Andraghetti G, Marenco S, Mazzucchelli C, Labanca S, Cordera R, Testa R, Picciotto A. HOMA, BMI, and Serum Leptin Levels Variations during Antiviral Treatment Suggest Virus-Related Insulin Resistance in Noncirrhotic, Nonobese, and Nondiabetic Chronic Hepatitis C Genotype 1 Patients. Gastroenterol Res Pract 2015;2015:975695. [PMID: 25821463 DOI: 10.1155/2015/975695] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
38 Martinez D, Palmer C, Simar D, Cameron BA, Nguyen N, Aggarwal V, Lloyd AR, Zekry A. Characterisation of the cytokine milieu associated with the up-regulation of IL-6 and suppressor of cytokine 3 in chronic hepatitis C treatment non-responders. Liver Int 2015;35:463-72. [PMID: 24461080 DOI: 10.1111/liv.12473] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
39 Abd El-Wahab EW, Mikheal A, Sidkey F, Shatat HZ. Insulin resistance as a predictor of early virologic response to HCV therapy among chronic HCV Egyptian patients. J Med Virol 2015;87:428-40. [PMID: 25583244 DOI: 10.1002/jmv.24092] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
40 Pol S, Vallet-pichard A. Optimal Management of HIV-HCV Coinfection. Curr Hepatology Rep 2014;13:295-303. [DOI: 10.1007/s11901-014-0244-4] [Reference Citation Analysis]
41 Abenavoli L, Masarone M, Peta V, Milic N, Kobyliak N, Rouabhia S, Persico M. Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3. World J Gastroenterol 2014; 20(41): 15233-15240 [PMID: 25386071 DOI: 10.3748/wjg.v20.i41.15233] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 50] [Article Influence: 5.4] [Reference Citation Analysis]
42 Negro F. Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. J Hepatol 2014;61:S69-78. [PMID: 25443347 DOI: 10.1016/j.jhep.2014.08.003] [Cited by in Crossref: 114] [Cited by in F6Publishing: 119] [Article Influence: 12.7] [Reference Citation Analysis]
43 Buti M, Esteban R. Hepatitis C virus genotype 3: a genotype that is not ‘easy-to-treat’. Expert Rev Gastroenterol Hepatol. 2015;9:375-385. [PMID: 25222289 DOI: 10.1586/17474124.2015.960396] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
44 Deborah Friedman N, Green JH, Weber HM, Stephen S, Lane SE, Ting AY, Watson JP. Hepatitis C virus treatment in the 'real-world': how well do 'real' patients respond? J Clin Exp Hepatol 2014;4:214-20. [PMID: 25755563 DOI: 10.1016/j.jceh.2014.07.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
45 Amano K, Kawaguchi T, Kuromatsu R, Kawaguchi A, Miyajima I, Ide T, Kakuma T, Sata M. Time trends of clinical characteristics in hepatocellular carcinoma patients with chronic hepatitis B virus infection: A field survey between 2000 and 2012. Mol Clin Oncol 2014;2:927-34. [PMID: 25279176 DOI: 10.3892/mco.2014.398] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
46 Chirikov VV, Shaya FT, Howell CD. Association between interferon use and reduced metabolic and vascular complications among patients with hepatitis C. Expert Rev Gastroenterol Hepatol 2014;8:973-83. [PMID: 25109401 DOI: 10.1586/17474124.2014.945911] [Reference Citation Analysis]
47 Tallón de Lara P, Himschoot T, Frossard JL, Negro F. Does telaprevir possess a direct antidiabetic effect? Liver Int 2014;34:967-9. [PMID: 24329983 DOI: 10.1111/liv.12440] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
48 Ampuero J, Romero-Gómez M, Reddy KR. Review article: HCV genotype 3 – the new treatment challenge. Aliment Pharmacol Ther 2014;39:686-98. [PMID: 24612116 DOI: 10.1111/apt.12646] [Cited by in Crossref: 89] [Cited by in F6Publishing: 80] [Article Influence: 9.9] [Reference Citation Analysis]
49 Gatselis NK, Zachou K, Saitis A, Samara M, Dalekos GN. Individualization of chronic hepatitis C treatment according to the host characteristics. World J Gastroenterol 2014; 20(11): 2839-2853 [PMID: 24659876 DOI: 10.3748/wjg.v20.i11.2839] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
50 Jiménez-Sousa MA, Berenguer J, Fernández-Rodríguez A, Micheloud D, Guzmán-Fulgencio M, Miralles P, Pineda-Tenor D, García-Álvarez M, López JC, Aldámiz-Echevarria T, Carrero A, Resino S. IL28RA polymorphism (rs10903035) is associated with insulin resistance in HIV/HCV-coinfected patients. J Viral Hepat 2014;21:189-97. [PMID: 24438680 DOI: 10.1111/jvh.12130] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
51 Rojas Á, del Campo JA, Maraver M, Aparcero R, García-Valdecasas M, Diago M, Carmona I, Andrade RJ, Solà R, Romero-Gómez M. Hepatitis C virus infection alters lipid metabolism depending on IL28B polymorphism and viral genotype and modulates gene expression in vivo and in vitro. J Viral Hepat 2014;21:19-24. [PMID: 24188401 DOI: 10.1111/jvh.12209] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
52 Romero-Gómez M, Del Campo JA. Insulin resistance, telaprevir, and virological response in hepatitis C: the debate must go on. Hepatology 2013;58:1874-6. [PMID: 23913755 DOI: 10.1002/hep.26642] [Reference Citation Analysis]
53 Younossi Z, Negro F, Serfaty L, Pol S, Diago M, Zeuzem S, Andreone P, Lawitz EJ, Roberts S, Focaccia R, Foster GR, Horban A, Lonjon-Domanec I, Coate B, DeMasi R, Picchio G, Witek J. Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial. Hepatology 2013;58:1897-906. [PMID: 24382638 DOI: 10.1002/hep.26437] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
54 Grasso A, Malfatti F, Testa R. Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C? World J Gastroenterol 2013; 19(41): 6947-6956 [PMID: 24222938 DOI: 10.3748/wjg.v19.i41.6947] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
55 Eslam M, Booth DR, George J, Ahlenstiel G. Interaction of IFNL3 with insulin resistance, steatosis and lipid metabolism in chronic hepatitis C virus infection. World J Gastroenterol 2013; 19(41): 7055-7061 [PMID: 24222948 DOI: 10.3748/wjg.v19.i41.7055] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
56 Juneja M, Euliano R, Satoskar R, Lewis JH. Polypharmacy and comorbidity are associated with a lower early virologic response in hepatitis C patients treated with first generation protease inhibitor triple therapy: a preliminary analysis. Dig Dis Sci 2013;58:3348-58. [PMID: 23925819 DOI: 10.1007/s10620-013-2812-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
57 Di Marco V, Covolo L, Calvaruso V, Levrero M, Puoti M, Suter F, Gaeta GB, Ferrari C, Raimondo G, Fattovich G, Santantonio T, Alberti A, Bruno R, Mussini C, Mondelli M, Donato F, Craxì A; Multicenter Italian Group for the Study of Hepatitis C. Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis. J Viral Hepat 2013;20:790-800. [PMID: 24168258 DOI: 10.1111/jvh.12106] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
58 Guo X, Jin M, Yang M, Liu K, Li JW. Type 2 diabetes mellitus and the risk of hepatitis C virus infection: a systematic review. Sci Rep. 2013;3:2981. [PMID: 25671325 DOI: 10.1038/srep02981] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
59 Villar LM, Del Campo JA, Ranchal I, Lampe E, Romero-Gomez M. Association between vitamin D and hepatitis C virus infection: A meta-analysis. World J Gastroenterol 2013; 19(35): 5917-5924 [PMID: 24124339 DOI: 10.3748/wjg.v19.i35.5917] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 67] [Article Influence: 6.6] [Reference Citation Analysis]
60 Laurito MP, Parise ER. Association between insulin resistance and sustained virologic response in hepatitis C treatment, genotypes 1 versus 2 and 3: systematic literature review and meta-analysis. Braz J Infect Dis 2013;17:555-63. [PMID: 24055394 DOI: 10.1016/j.bjid.2013.02.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
61 Maasoumy B, Manns MP, Cornberg M. Extrahepatic Manifestations of Hepatitis C Virus Infection. Viral Hepatitis 2013. [DOI: 10.1002/9781118637272.ch20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
62 Butt Z, Jadoon NA, Salaria ON, Mushtaq K, Riaz IB, Shahzad A, Hashmi AM, Sarwar S. Diabetes mellitus and decompensated cirrhosis: risk of hepatic encephalopathy in different age groups. J Diabetes. 2013;5:449-455. [PMID: 23731902 DOI: 10.1111/1753-0407.12067] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
63 Itou M, Kawaguchi T, Taniguchi E, Sata M. Dipeptidyl peptidase-4: A key player in chronic liver disease. World J Gastroenterol 2013; 19(15): 2298-2306 [PMID: 23613622 DOI: 10.3748/wjg.v19.i15.2298] [Cited by in CrossRef: 124] [Cited by in F6Publishing: 133] [Article Influence: 12.4] [Reference Citation Analysis]
64 Younossi ZM, Stepanova M, Nader F, Younossi Z, Elsheikh E. Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment Pharmacol Ther 2013;37:647-52. [PMID: 23384408 DOI: 10.1111/apt.12234] [Cited by in Crossref: 116] [Cited by in F6Publishing: 104] [Article Influence: 11.6] [Reference Citation Analysis]
65 Miyajima I, Kawaguchi T, Fukami A, Nagao Y, Adachi H, Sasaki S, Imaizumi T, Sata M. Chronic HCV infection was associated with severe insulin resistance and mild atherosclerosis: a population-based study in an HCV hyperendemic area. J Gastroenterol 2013;48:93-100. [PMID: 22678465 DOI: 10.1007/s00535-012-0610-3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
66 Del Campo JA, Ampuero J, Rojas L, Conde M, Rojas A, Maraver M, Millán R, García-Valdecasas M, García-Lozano JR, González-Escribano MF, Romero-Gómez M. Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism. Aliment Pharmacol Ther 2013;37:74-80. [PMID: 23121166 DOI: 10.1111/apt.12113] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
67 Song S, Paik H, Song Y. The relationship between intake of nutrients and food groups and insulin resistance in Korean adults: Using the Fourth Korea National Health and Nutrition Examination Survey (KNHANES IV, 2007-2009). Korean J Nutr 2013;46:61. [DOI: 10.4163/kjn.2013.46.1.61] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
68 Kobayashi Y, Iwasa M, Miyachi H, Sugimoto R, Tanaka H, Mifuji-moroka R, Fujita N, Sumida Y, Takei Y. Effect of Iron-Mediated Oxidative Stress on Insulin Resistance Through the Forkhead Box-Containing Protein O Subfamily-1 (FOXO-1) Pathway in Chronic Hepatitis C. IJCM 2013;04:10-18. [DOI: 10.4236/ijcm.2013.41004] [Reference Citation Analysis]
69 Yasutake K, Kohjima M, Nakashima M, Kotoh K, Nakamuta M, Enjoji M. Nutrition therapy for liver diseases based on the status of nutritional intake. Gastroenterol Res Pract 2012;2012:859697. [PMID: 23197979 DOI: 10.1155/2012/859697] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
70 Aghemo A, Prati GM, Rumi MG, Soffredini R, D'Ambrosio R, Orsi E, De Nicola S, Degasperi E, Grancini V, Colombo M. Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. Hepatology 2012;56:1681-7. [PMID: 22619107 DOI: 10.1002/hep.25867] [Cited by in Crossref: 74] [Cited by in F6Publishing: 64] [Article Influence: 6.7] [Reference Citation Analysis]
71 Rice JP, Burnett D, Tsotsis H, Lindstrom MJ, Cornett DD, Voermans P, Sawyer J, Striker R, Lucey MR. Comparison of hepatitis C virus treatment between incarcerated and community patients. Hepatology 2012;56:1252-60. [PMID: 22505121 DOI: 10.1002/hep.25770] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
72 Hull MW, Rollet K, Moodie EE, Walmsley S, Cox J, Potter M, Cooper C, Pick N, Saeed S, Klein MB; Canadian Co-infection Cohort Study Investigators. Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/hepatitis C virus-coinfected patients. AIDS 2012;26:1789-94. [PMID: 22739388 DOI: 10.1097/QAD.0b013e32835612ce] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
73 Ogawa E, Furusyo N, Murata M, Ikezaki H, Ihara T, Hayashi T, Toyoda K, Taniai H, Okada K, Kainuma M, Hayashi J. Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1. J Hepatol 2012;57:534-40. [PMID: 22613000 DOI: 10.1016/j.jhep.2012.04.027] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
74 Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy. J Med Virol 2012;84:1593-9. [DOI: 10.1002/jmv.23368] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
75 Kappel CR, Kretzmann NA, Alvares-da-Silva MR. IRS1 Expression in Hepatic Tissue and Leukocytes in Chronic Hepatitis C Virus Infected Patients: A Comparative Study. Int J Hepatol 2012;2012:698905. [PMID: 22830036 DOI: 10.1155/2012/698905] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
76 Kawaguchi T, Taniguchi E, Sata M. Motor vehicle accidents: How should cirrhotic patients be managed? World J Gastroenterol 2012; 18(21): 2597-2599 [PMID: 22690067 DOI: 10.3748/wjg.v18.i21.2597] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
77 Enjoji M, Kohjima M, Kotoh K, Nakamuta M. Metabolic disorders and steatosis in patients with chronic hepatitis C: metabolic strategies for antiviral treatments. Int J Hepatol. 2012;2012:264017. [PMID: 22701799 DOI: 10.1155/2012/264017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
78 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ; American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastroenterological Association. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol 2012;107:811-26. [PMID: 22641309 DOI: 10.1038/ajg.2012.128] [Cited by in Crossref: 270] [Cited by in F6Publishing: 280] [Article Influence: 24.5] [Reference Citation Analysis]
79 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-23. [PMID: 22488764 DOI: 10.1002/hep.25762] [Cited by in Crossref: 2379] [Cited by in F6Publishing: 2221] [Article Influence: 216.3] [Reference Citation Analysis]
80 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ; American Gastroenterological Association, American Association for the Study of Liver Diseases, American College of Gastroenterologyh. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012;142:1592-609. [PMID: 22656328 DOI: 10.1053/j.gastro.2012.04.001] [Cited by in Crossref: 1205] [Cited by in F6Publishing: 1271] [Article Influence: 109.5] [Reference Citation Analysis]
81 Butt AA, Umbleja T, Andersen JW, Sherman KE, Chung RT; ACTG A5178 Study Team. Impact of peginterferon alpha and ribavirin treatment on lipid profiles and insulin resistance in Hepatitis C virus/HIV-coinfected persons: the AIDS Clinical Trials Group A5178 Study. Clin Infect Dis 2012;55:631-8. [PMID: 22563020 DOI: 10.1093/cid/cis463] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
82 Eslam M, Aparcero R, Mousa YI, Grande L, Shaker Y, Ali A, Del Campo JA, Khattab MA, Romero-Gomez M. Insulin resistance impairs viral dynamics independently of ethnicity or genotypes. J Clin Gastroenterol 2012;46:228-34. [PMID: 22298085 DOI: 10.1097/MCG.0b013e31822a2dc6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
83 Eslam M, López-cortés LF, Romero-gomez M. The role of insulin resistance in HIV/hepatitis C virus-coinfected patients: . Current Opinion in HIV and AIDS 2011;6:553-8. [DOI: 10.1097/coh.0b013e32834bd21d] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]